2018, a new era for PhysioStim

Welcome to PhysioStim 2.0!

A new era for preclinical cardiac electrophysiology

Time flies by and we’ve already reached the end of January but the entire PhysioStim team would still like to take this opportunity to wish you a very happy and prosperous year 2018. We especially would like to thank our clients for their confidence over the past few years and make a few announcements for the year to come.

The European Centre of Excellence for Nonclinical Cardiac Electrophysiology

As we anticipate the growing need of the pharmaceutical industry and biotech companies to conduct high quality preclinical assays in order to derisk new compounds, we recently teamed up with Apconix to create a European Centre of Excellence for Nonclinical Cardiac Electrophysiology. The PhysioStim-Apconix alliance is designed to help companies make better decisions when it comes to selecting the optimal clinical lead candidate at an early stage.

A full-fledged range of cardiac safety studies for new compounds

Both PhysioStim and Apconix combine their extensive expertise in cardiotoxicity to offer a complete range of preclinical cardiac safety studies, ranging from screening to customized problem-solving studies to offer a full package of study models, including in vitro and in vivo solutions. Studies can be conducted in a GLP and non-GLP format: we provide an integrated solution and high-quality service based on our expertise.

One single contact to cover all your studies

Over the years, PhysioStim has consistently risen to the challenge of designing and conducting high quality studies. We value our customers and guide their preclinical studies with innovative, robust ideas. Our scientists are recognized for their expertise, reactivity, motivation and awarded with the loyalty of our customers. One-to-one customer relations are key to our business. The new alliance with Apconix will not change the way we work. You’ll still have a single contact person to guide your ongoing and upcoming projects and help you determine the best solution to evaluate your drug candidate in terms of cardiac safety.

Come meet the team – save the date

Should you like to learn more about PhysioStim, our alliance with Apconix and our range of studies, don’t hesitate to come meet us at:

  • BioSpring – Amsterdam, The Netherlands – March 12th-14th, 2018
  • Innovation and New Trends in Safety and Toxicity – B4B-Connection – Lyon, France – May, 23th-24th, 2018
  • BIO – Boston, USA– June, 4th-7th, 2018
  • Eurotox – Brussels, Belgium – September 2nd-5th, 2018
  • SPS – Washington DC, USA – September 30th– October-3rd, 2018

“We're already looking forward to seeing you there.”

dr. marie le grand
CEO

About Physiostim

PhysioStim is a French GLP-certified preclinical CRO with over 17 years of expertise in the field of cardiovascular pharmacology and electrophysiology. Our team determines your best drug candidate and derisks compounds in terms of cardiac safety. In 2018, more than ever, our main goal remains to deliver state-of-the-art cardiovascular safety studies while providing excellent customer service.

Should you require further information, don't hesitate to contact us

Comments are closed.